A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

References

• ConnorCAttaiDAdjuvant endocrine therapy for the surgeon: options, side effects, and their managementAnn Surg Oncol201320103188319323975307
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMAromatase inhibitors in breast cancerNew Engl J Med2003348242431244212802030
   PubMed Web of Science ®Google Scholar
• ForbesJFCuzickJBuzdarAHowellATobiasJSBaumMArimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ GroupEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol200891455318083636
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIBaumMATAC/LATTE InvestigatorsEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialLancet Oncol201011121135114121087898
   PubMed Web of Science ®Google Scholar
• DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative GroupLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med2003349191793180214551341
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMABCSG and the GABGSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABC SG trial 8 and ARNO 95 trialLancet2005366948445546216084253
   PubMed Web of Science ®Google Scholar
• BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerJ Clin Oncol201028233784379620625130
   PubMed Web of Science ®Google Scholar
• van de VeldeCJReaDSeynaeveCAdjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialLancet2011377976232133121247627
   PubMed Web of Science ®Google Scholar
• MouridsenHGiobbie-HurderAGoldhirschABIG 1-98 Collaborative GroupLetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med2009361876677619692688
   PubMed Web of Science ®Google Scholar
• AphinivesPVachirodomDThanapaisalCRangsrikajeeDSomintaraOEffects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapyBreast Cancer (Dove Med Press)2014614515025249759
   PubMedGoogle Scholar
• DixonJMRenshawLLangridgeCAnastrozole and letrozole: an investigation and comparison of quality of life and tolerabilityBreast Cancer Res Treat2011125374174920821047
   PubMed Web of Science ®Google Scholar
• RiemsmaRForbesCAKesselsASystematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancerBreast Cancer Res Treat2010123192420535542
   PubMed Web of Science ®Google Scholar
• GeislerJDifferences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?Br J Cancer201110471059106621364577
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNPritchardKIExemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trialJ Clin Oncol201331111398140423358971
   PubMed Web of Science ®Google Scholar
• EllisMJSumanVJHoogJRandomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031J Clin Oncol201129172342234921555689
   PubMed Web of Science ®Google Scholar
• FabianCJThe what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerInt J Clin Pract200761122051206317892469
   PubMed Web of Science ®Google Scholar
• BeresfordMTumurIChakrabartiJBardenJRaoNMakrisAA qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancerClin Oncol (R Coll Radiol)201123320921521134732
   PubMed Web of Science ®Google Scholar
• FonteinDBSeynaeveCHadjiPSpecific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysisJ Clin Oncol201331182257226423610112
   PubMed Web of Science ®Google Scholar
• FrieseCRPiniTMLiYAdjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancerBreast Cancer Res Treat2013138393193923542957
   PubMed Web of Science ®Google Scholar
• BerryJAre all aromatase inhibitors the same? A review of controlled clinical trials in breast cancerClin Ther200527111671168416368441
   PubMed Web of Science ®Google Scholar
• ThürlimannBKeshaviahACoatesASBreast International Group (BIG) 1-98 Collaborative GroupA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• AmirESerugaBNiraulaSCarlssonLOcañaAToxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysisJ Natl Cancer Inst2011103171299130921743022
   PubMed Web of Science ®Google Scholar
• FallowfieldLCellaDCuzickJFrancisSLockerGHowellAQuality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer TrialJ Clin Oncol200422214261427115514369
   PubMed Web of Science ®Google Scholar
• ThomasRExamining quality of life issues in relation to endocrine therapy for breast cancerAm J Clin Oncol2003264S40S4412902876
   PubMed Web of Science ®Google Scholar
• ThomasRGodwardSMakrisABloomfieldDMoodyAMWilliamsMGiving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozoleClin Oncol (R Coll Radiol)200416748549115490811
   PubMed Web of Science ®Google Scholar